Insider buying last 90 days
No open-market insider purchases were filed for DVA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every DVA insider filing, plotted on the chart in Gekko.Open DVA in Gekko
Gekko Brief
AI summaryDaVita's stock has been under pressure following its Q2 earnings report, where investor attention centered on declining revenue per treatment even as adjusted EPS rose. Commentary this week continued to focus on this theme, noting the stock's underperformance against the S&P 500 over the past three months despite stronger year-to-date and 52-week gains. A Form 4 insider filing was also noted during the period.
DVA closed at $178.07, essentially flat on the day, with price sitting between its 50-day average of $194.12 and 200-day average of $168.95, reflecting a mixed trend picture. The GekkoIndex reads 63.6, placing the stock in the Accumulation zone. Price sits 15.9% below Gekko Fair Value of $211.69.
The next earnings report is scheduled for 4 November 2026, after the close, 36 days out and beyond a typical 20-trading-day holding window. In the past 30 days, one unusual options signal was recorded, with call premium of $2,331,682 and no put premium. One billionaire holder is noted in current positioning. Seasonality data covering five years shows the next 20 trading days have averaged a decline of -3.3%, higher in only 1 of those years. Analyst consensus across 6 firms stands at 3 buy, 2 hold, and 1 sell, with a consensus target of $219.86.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
DaVita price vs fair value
Close $178.07200-day averageGekko Fair Value $211.69
DaVita quick facts
- Market cap
- $11.43B
- P/E ratio
- 15.1
- Forward P/E
- 10
- EPS, TTM
- $11.80
- Revenue, TTM
- $14.01B
- Profit margin
- 6.1%
- Dividend yield
- —
- Beta
- 0.83
- Volume
- 439,234 avg 712,173
- 1-year return
- +36.7%
- Typical daily move
- ±3.2%
- Typical 20-day move
- ±5.8%
- 50-day average
- $194.12
- 200-day average
- $168.95
- Next earnings
- Nov 4 after close
- Shares outstanding
- 63.80M
DaVita swing-trade checklist
DaVita scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $178.07 sits between the 50-day ($194.12) and 200-day ($168.95) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
63.6, Accumulation
Reading 63.6 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
15.9% below
Price is 15.9% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 30 days: 1 unusual options signal.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 4, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−3.3% on average
From this point in the calendar, the next 20 trading days averaged −3.3% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
DaVita stock chart and price history
DaVita closed at $178.07 on Sep 28, 2026, +36.7% over the past year, inside a 52-week range of $101.00 to $247.49.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −0.5%
- 3 months
- −18.9%
- 6 months
- +15.3%
- 1 year
- +36.7%
The full DVA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open DVA in Gekko
Follow DaVita through every session
Put DVA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track DVA in GekkoFree for 7 days. No credit card required.
About DaVita
DaVita provides dialysis care for people living with chronic kidney failure, treating patients mainly through outpatient centers while also offering care in hospitals and in patients' homes. The company runs its own laboratories to handle routine testing for dialysis patients and other physician-ordered analyses for those with end-stage renal disease, and it is widely recognized for this combination of direct treatment and lab support.
Beyond patient care, DaVita provides administrative and management services to other outpatient dialysis facilities and runs chronic disease management programs, including risk-based and other integrated care arrangements for patients with kidney disease. Its offerings also include vascular access procedures, clinical research work, physician support services, and broader kidney care programs. Together these operations serve patients across a large network of outpatient centers in the United States and in other countries, along with acute dialysis and laboratory services delivered inside hospitals.
DaVita was founded in 1994 and is headquartered in Denver, Colorado. It previously operated under the name DaVita HealthCare Partners Inc. before adopting its current name in September 2016. Its shares are listed on the NYSE under the ticker DVA.
- Listed
- NYSE
- Sector
- Health services
- Industry
- Medical/Nursing services
- Website
- davita.com
DaVita GekkoIndex: the smart money zone
DaVita’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 63.6, in the Accumulation zone, up 0.4 points over five sessions.
63.6Accumulation
Up 0.4 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 42 | +1.5% | +10.0% | ||
| Accumulation (current zone) | 196 | +1.3% | +4.8% | ||
| Neutral | 371 | −0.1% | −0.2% | ||
| Distribution | 56 | +1.9% | +4.5% | ||
| Selling | 7 | Too few readings yet | |||
Average DVA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the DVA price, zone by zone.Track DVA in Gekko
Is DaVita stock overvalued? Gekko Fair Value
DaVita trades 15.9% below Gekko Fair Value of $211.69, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what DaVita shares are worth, recalculated every trading day.
$211.69
Gekko Fair Value, Sep 29, 2026
15.9% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open DVA in Gekko
DaVita insider and Congress trading
No open-market insider purchases were filed for DaVita, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in DVA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for DVA, plotted on the chart in Gekko.Open DVA in Gekko
Buybacks
DaVita has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $364.4M
- As a share of market cap
- 3.19%
- Trailing four quarters
- $1.56B
From company filings.
Unusual options activity last 30 days
1signal, 100% of the flagged premium in calls.
Latest: Bullish flow on Sep 19, $2.33M in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds DVA.
0added0opened1trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
DaVita earnings: next date and track record
DaVita reports on Nov 4, 2026, after the close (36 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 36 days away
- EPS estimate
- $3.55
- Revenue estimate
- $3.52B
6 of 8reports beat the EPS estimate
±13%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 4, 2026 AI summary
- What they said
- DaVita reported Q2 2026 results broadly in line with expectations, with year-over-year volume growth accelerating slightly faster than anticipated due to improved mortality rates. Revenue per treatment declined sequentially due to lower commercial mix from declining ACA enrollment and reduced phosphate binder contributions. Management highlighted successful phosphate binder bundle transition, reducing patients on less effective OTC options by over 50%. CMS proposed 2027 ESRD payment rule includes a base rate increase tracking below industry cost trends.
- Guidance
- Management will provide updated full-year guidance later in the call. CMS proposed 2027 rate increase tracks below cost trends; final rule impact on phosphate binders remains uncertain. DaVita targets return to at least 2% treatment volume growth by 2029.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | $4.02 est $4.01 | $3.55B est $3.50B | −19.3% |
| May 5, 2026 | $2.87 est $2.41 | $3.42B est $3.36B | +25.8% |
| Feb 2, 2026 | $3.40 est $3.24 | $3.62B est $3.51B | +23.2% |
| Oct 29, 2025 | $2.51 est $3.17 | $3.42B est $3.43B | −8.4% |
| Aug 5, 2025 | $2.95 est $2.70 | $3.38B est $3.44B | −8.4% |
| May 12, 2025 | $2.00 est $1.95 | $3.22B est $3.21B | +0.2% |
| Feb 13, 2025 | $2.24 est $2.14 | $3.29B est $3.27B | −8.5% |
| Oct 29, 2024 | $2.59 est $2.72 | $3.26B est $3.27B | −10.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
DaVita stock forecast and analyst price targets
Analysts’ average 12-month price target for DaVita is $219.86, +23.5% from the last close, from 6 firms rating the stock in the last 90 days.
$219.86consensus 12-month target, +23.5% from the last close
Now $178.07Avg $219.86
Low $215High $270
Each firm’s latest rating in the last 90 days: 6 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 11 | Barclays | $224 | +25.8% |
| Aug 7 | Truist Financial | $215 | +20.7% |
| Aug 7 | TD Cowen | $220 | +23.5% |
| Aug 5 | Deutsche Bank | $265 | +48.8% |
| Aug 5 | Bank of America Securities | — | — |
+4.8%average 20-day move after past Accumulation readings
−3.3%average move over the next 20 trading days in the last 5 years
±3.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
DaVita seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, DaVita averaged −3.3% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.7% | 1 of 5 |
| Next 10 trading days | −6.3% | 1 of 5 |
| Next 15 trading days | −3.6% | 1 of 5 |
| Next 20 trading days | −3.3% | 1 of 5 |
| Next 30 trading days | −11.8% | 0 of 5 |
For scale, DVA’s typical 20-trading-day move in either direction is about 5.8%.
DaVita market cap and key statistics
DaVita’s market cap is $11.43B, with a P/E ratio of 15.1 and revenue of $14.01B over the last twelve months.
Valuation
- Market cap
- $11.43B
- P/E ratio
- 15.1
- Forward P/E
- 10
- EPS, TTM
- $11.80
- Gekko Fair Value
- $211.69
Trading
- Volume
- 439,234
- Avg volume, 20 days
- 712,173
- 52-week high
- $247.49
- 52-week low
- $101.00
- Shares outstanding
- 63.80M
Financials
- Revenue, TTM
- $14.01B
- Profit margin
- 6.1%
- Return on equity
- 88.5%
- Quarterly earnings growth, YoY
- +55.8%
Risk and income
- Beta
- 0.83
- Typical daily move
- ±3.2%
- Typical 20-day move
- ±5.8%
DaVita stock news this week
Coverage of DaVita this week reads positive: 5 positive, 3 neutral and 3 negative headlines.
- DaVita HealthCare Partners Inc Stock Price Live, Charts & NewsThe Economic Times, Sep 26
- Is DaVita Stock Underperforming the S&P 500?Webull, Sep 25
- Form 4 DaVita HealthCare Partners For: 25 September By Investing.comInvesting.com Canada, Sep 25
- DaVita stock heads into the open after September 24 lossAD HOC NEWS, Sep 25
- DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research, Sep 24
- DaVita Inc. stock underperforms Thursday when compared to competitorsMarketWatch, Sep 24
DaVita peers
DaVita’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Accumulation | 3.9% below |
| GHGuardant Health | Neutral | 0.5% above |
| SOLVSolventum | Neutral | 16.4% below |
| EHCEncompass Health | Neutral | 7.6% above |
| BTSGBrightSpring Health Services | Accumulation | 7.4% below |
| ENSGEnsign | Neutral | 11.2% above |
A peer links to its own page where one exists.
DaVita stock FAQ
What is DaVita’s market cap?
DaVita’s market cap is $11.43B at the Sep 28, 2026 close of $178.07, with 63.80M shares outstanding. The shares trade on a P/E ratio of 15.1.
What is the DaVita stock forecast?
The consensus analyst 12-month price target for DaVita is $219.86, +23.5% from the last close. Of the 6 firms that rated the stock in the last 90 days, 3 rate it a buy, 2 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is DaVita stock overvalued or undervalued?
On Gekko’s estimate DaVita is undervalued: the Sep 28, 2026 close of $178.07 is 15.9% below Gekko Fair Value of $211.69. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does DaVita report earnings next?
DaVita is expected to report on Nov 4, 2026, after the market closes (36 days away). Analysts expect earnings of $3.55 per share on revenue of $3.52B. DaVita beat the earnings estimate in 6 of its last 8 reports, moving 13% on average across the report.
What is DaVita’s 52-week high and low?
DaVita’s 52-week high is $247.49 and its 52-week low is $101.00; it closed at $178.07 on Sep 28, 2026, +36.7% over the past year.
Is DaVita stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in DaVita?
Gekko flagged 1 unusual options signal in DaVita over the last 30 days, with $2.33M of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Sep 19, 2026 with $2.33M in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See DaVita the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.